ArticleFrontiers in immunology2022
CD8
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Myeloperoxidase promotes a tumorigenic microenvironment in non-small cell lung cancer.Redox biology · 2026Article
- A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signatures.Cancer immunology, immunotherapy : CII · 2025Article
- A Pan-Cancer Comparative Analysis of The Cancer Genome Atlas Transcriptomic TIL-Immune Signatures.Research square · 2025Article
- Hsa-miR-21 promoted the progression of lung adenocarcinoma by regulating LRIG1 expression.BMC pulmonary medicine · 2025Article
- MOGAN for LUAD Subtype Classification by Integrating Three Omics Data Types.Cancer innovation · 2025Article
- Identification of the molecular subtype and prognostic characteristics of lung adenocarcinoma based on CD8Cancer biomarkers : section A of Disease markers · 2024Article
- A Study of Disease Prognosis in Lung Adenocarcinoma Using Single-Cell Decomposition and Immune Signature Analysis.Cancers · 2024Article
- Article
- Prognostic effect of TCF1+ CD8+ T cell and TOX+ CD8+ T cell infiltration in lung adenocarcinoma.Cancer science · 2024Article
- Developing a prognostic model using machine learning for disulfidptosis related lncRNA in lung adenocarcinoma.Scientific reports · 2024Article
- HERVK-mediated regulation of neighboring genes: implications for breast cancer prognosis.Retrovirology · 2024Article
- Article
- Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing.Therapeutic advances in medical oncology · 2024Review
- An Aging-Related lncRNA Signature Establishing for Breast Cancer Prognosis and Immunotherapy Responsiveness Prediction.Pharmacogenomics and personalized medicine · 2024Article
- Article
- Regulatory T cells in lung disease and transplantation.Bioscience reports · 2023Review
- Targeting tumor microenvironment for non-small cell lung cancer immunotherapy.Chinese medical journal pulmonary and critical care medicine · 2023Review
- Comprehensive Explorations of CCL28 in Lung Adenocarcinoma Immunotherapy and Experimental Validation.Journal of inflammation research · 2023Article
- Pan-cancer Analysis of the Disulfidptosis-related Gene NCKAP1 and Its Prognostic Value for Lung Adenocarcinoma.Journal of Cancer · 2023Article
- The effect of SMAD4 on the prognosis and immune response in hypopharyngeal carcinoma.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The presence of infiltrating CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.